| Document Date: 2014-06-09 09:13:18
Open Document File Size: 253,51 KBShare Result on Facebook
City San Diego / Cambridge / / Company Astex Pharmaceuticals Inc. / / Country United Kingdom / / Event FDA Phase / / MedicalCondition HCC827 xenograft model Tumor / HCC827 tumors / tumor / xenograft tumors The AT13387 / Mice bearing NCI-H1650 tumor / significant tumor / NCI-H1650 tumor / xenograft tumors / non-small cell lung cancer / NSCLC / EGFR-driven disease / pS6 Actin Mice bearing HCC827 tumor / Relative tumor / mg/kg Erlotinib Tumor / / Person Keisha Hearn / Jon Lewis / Aurélie Courtin / Erlotinib Tumor / Neil Thompson / Nicola Wallis / John Lyons / / / Position HCC827 xenograft model / / Product ALK / / Technology Genotype / antibodies / / URL www.astx.com / /
SocialTag |
The HSP90 inhibitor, AT13387, combined with erlotinib improves response in EGFR-driven xenograft models of NSCLC[removed]Tomoko Smyth, Jon Lewis, Keisha Hearn, Aurélie Courtin, Neil Thompson, John Lyons, Nicola Wallis 1As